范可尼贫血社区对产前干预的态度调查
本研究通过在线问卷调查了18个国家72名范可尼贫血(FA)患者及照护者对产前诊断、宫内治疗和临床试验的态度。结果显示,76%愿意在FDA批准后接受宫内造血干细胞移植,68%会考虑参加相关临床试验,71%会在任何有风险的妊娠中接受侵入性产前检测以确认FA,56%不太可能终止受累妊娠。结论认为该社区对产前诊断和治疗持积极态度,支持推进宫内细胞和基因治疗临床试验。
要点
- 76%的FA社区成员愿意在FDA批准后接受宫内造血干细胞移植。
- 68%会考虑参加评估宫内HSCT或基因治疗安全性和有效性的临床试验。
- 71%愿意在任何有风险的妊娠中接受侵入性产前检测以确认FA,56%不太可能终止受累妊娠。
核心结论
- 范可尼贫血社区对产前诊断和宫内治疗持积极态度,支持推进宫内细胞和基因治疗临床试验。
研究设计与样本
- 多学科团队通过领先的FA患者倡导组织创建并分发在线调查,收集受访者人口学、病史和治疗数据,使用单变量有序逻辑回归分析态度。
- 共72名来自18个国家的FA社区成员完成调查。
主要发现
- 76%的受访者愿意在FDA批准后接受宫内造血干细胞移植(IU-HSCT)。
- 68%的受访者会考虑参加评估IU-HSCT或宫内基因治疗安全性和有效性的临床试验。
- 71%的受访者会在任何有风险的妊娠中接受侵入性产前检测以确认FA。
- 56%的受访者不太可能终止受累妊娠。
临床怎么用
- 调查结果提示FA社区对产前诊断和宫内治疗接受度较高,可支持相关临床试验的推进和社区态度持续评估。
局限性
- 电子调查具有固有局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In-utero cell and gene therapies may offer prenatal treatment options for inherited diseases. Preclinical data suggests in-utero (IU) hematopoietic stem cell transplantation (HSCT) could prevent Fanconi anemia (FA) related bone marrow failure without genotoxic conditioning or immune suppression. This study surveyed patient and caregiver attitudes within the FA community toward prenatal diagnosis, interventions, and clinical trials. METHODS: A multidisciplinary team created and distributed an online survey through the leading FA patient advocacy group. Respondents' demographic, history, and treatment data were collected, and their attitudes toward prenatal diagnosis, IU therapies, and pregnancy termination were analyzed using univariable ordinal logistic regression. RESULTS: 72 members from 18 countries completed the survey. Among the respondents, 76% were willing to undergo IU-HSCT if it was FDA approved, whereas 68% would consider enrolling in a clinical trial to assess the safety and efficacy of IU-HSCT or IU-gene therapy. 71% would undergo invasive prenatal testing in any at risk pregnancy to confirm FA and 56% were unlikely to terminate an affected pregnancy. CONCLUSION: In-utero therapy is a developing alternate treatment strategy for rare, inherited diseases. Although electronic surveys have inherent limitations, this tool enabled efficient assessment of FA community attitudes with a favorable response to prenatal diagnosis and therapies. These insights encourage efforts to advance IU-cell and gene therapy clinical trials and to continue to evaluate community attitudes as these therapies develop. This work may also provide insights into the attitudes of other rare inherited disease communities.
引用
- Lum T, Lee C, MacKenzie T, et al. Attitudes Toward Prenatal Interventions in the Fanconi Anemia Community. Prenat Diagn. 2026. PMID: 41711672. doi:10.1002/pd.70077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。